TY - JOUR
T1 - An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
AU - Vacca, Michele
AU - Kamzolas, Ioannis
AU - Harder, Lea Mørch
AU - Oakley, Fiona
AU - Trautwein, Christian
AU - Hatting, Maximilian
AU - Ross, Trenton
AU - Bernardo, Barbara
AU - Oldenburger, Anouk
AU - Hjuler, Sara Toftegaard
AU - Ksiazek, Iwona
AU - Lindén, Daniel
AU - Schuppan, Detlef
AU - Rodriguez-Cuenca, Sergio
AU - Tonini, Maria Manuela
AU - Castañeda, Tamara R.
AU - Kannt, Aimo
AU - Rodrigues, Cecília M.P.
AU - Cockell, Simon
AU - Govaere, Olivier
AU - Daly, Ann K.
AU - Allison, Michael
AU - Honnens de Lichtenberg, Kristian
AU - Kim, Yong Ook
AU - Lindblom, Anna
AU - Oldham, Stephanie
AU - Andréasson, Anne Christine
AU - Schlerman, Franklin
AU - Marioneaux, Jonathon
AU - Sanyal, Arun
AU - Afonso, Marta B.
AU - Younes, Ramy
AU - Amano, Yuichiro
AU - Friedman, Scott L.
AU - Wang, Shuang
AU - Bhattacharya, Dipankar
AU - Simon, Eric
AU - Paradis, Valérie
AU - Burt, Alastair
AU - Grypari, Ioanna Maria
AU - Davies, Susan
AU - Driessen, Ann
AU - Yashiro, Hiroaki
AU - Pors, Susanne
AU - Worm Andersen, Maja
AU - Feigh, Michael
AU - Yunis, Carla
AU - Bedossa, Pierre
AU - Sandt, Estelle
AU - Tonini, Maria Manuela
AU - The LITMUS Investigators
N1 - Funding:
We are indebted to the IBBL Pathology Team for staining and scanning
the histological slides; J. Cox for help with Biorender (Fig. 1); and the
companies producing the animal diets for providing details of the
diets’ composition upon request. This manuscript is written in memory
of Julia Brosnan (Pfizer), who contributed to the study design when
she was LITMUS industry lead. This study was conducted as part of
the preclinical work package of the LITMUS project. The LITMUS study
is a large, multi-center study aiming to evaluate NAFLD biomarkers.
The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking
under grant agreement 777377 funded the LITMUS study. This Joint
Undertaking receives support from the European Union’s Horizon
2020 research and innovation program and the European Federation
of Pharmaceutical Industries and Associations (EFPIA). European
Bioinformatics Institute (EMBL-EBI) core funding supported E.P. and
I. Kamzolas through funding and computing resources from EMBL-EBI.
Funding from the Medical Research Council (MRC) supported I.
Kamzolas. M.V. is supported by the University of Bari (Horizon Europe
Seed COD ID S06-miRNASH), the Foundation for Liver Research
(Intramural Funding), Associazione Italiana Ricerca sul Cancro (IG2022
grant no. 27521) and Ministry of University and Research on Next
Generation EU Funds (COD: P202222FCC, CUP: H53D23009960001,
DD MUR 1366 (01-09-2023), ‘System Biology’ Approaches in HCV
Patients with Residual Hepatic Steatosis after Viral Eradication; Cod
PE00000003, CUP: H93C22000630001, DD MUR 1550, ‘ON Foods—
Research and innovation network on food and nutrition Sustainability,
Safety and Security—Working ON Foods’; COD: CN00000041, CUP:
H93C22000430007, PNRR ‘National Center for Gene Therapy and
Drugs based on RNA Technology’, M4C2-Investment 1.4; Code:
CN00000013, CUP: H93C22000450007, PNNR: ‘National Centre for
HPC, Big Data and Quantum Computing’). A.V.-P. is funded by MRC
Metabolic Diseases Unit (MC_UU_00014/5): Disease Model Core,
Biochemistry Assay Lab, Histology Core and British Heart Foundation.
F.O. is funded by UK MRC program grants MR/K0019494/1 and MR/
R023026/1. C.M.P.R. is supported by Fundação para a Ciência e
Tecnologia (PTDC/MED-FAR/3492/2021) and La Caixa Foundation
(LCF/PR/HR21/52410028). Q.M.A. is supported by the Newcastle
NIHR Biomedical Research Centre. S.L.F. and W.S. are supported
by the National Institutes of Health (NIH) (NIH R01 DK128289; NCI
5P30CA196521-08 to S.L.F.; NIH R01 DK136016 to W.S.)
© 2024. The Author(s).
PY - 2024/6/12
Y1 - 2024/6/12
N2 - Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.
AB - Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.
KW - Animals
KW - Humans
KW - Disease Models, Animal
KW - Mice
KW - Non-alcoholic Fatty Liver Disease/metabolism
KW - Male
KW - Liver/metabolism
KW - Metabolic Diseases/metabolism
KW - Diet, Western/adverse effects
KW - Retrospective Studies
KW - Liver Cirrhosis/metabolism
UR - http://www.scopus.com/inward/record.url?scp=85195930089&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38867022/
U2 - 10.1038/s42255-024-01043-6
DO - 10.1038/s42255-024-01043-6
M3 - Article
C2 - 38867022
AN - SCOPUS:85195930089
SN - 2522-5812
VL - 6
SP - 1178
EP - 1196
JO - Nature Metabolism
JF - Nature Metabolism
IS - 6
ER -